None
Quote | AN2 Therapeutics Inc. (NYSE:ANTX)
Last: | $ |
---|---|
Change Percent: | -1.27% |
Open: | $57.76 |
Close: | $56.86 |
High: | $58.14 |
Low: | $56.86 |
Volume: | 315,708 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | AN2 Therapeutics Inc. (NYSE:ANTX)
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) rose 4.6% to $128.28 on volume of 215,349,874 shares Zoomcar Holdings Inc. (ZCAR) rose 34.0% to $0.183 on volume of 204,010,215 shares Maxeon Solar Technologies Ltd. (MAXN) fell 3.5% to $0.1736 on volume of 2...
2024-05-15 10:42:04 ET More on AN2 Therapeutics Spotlight On Nvidia, Walmart, Palo Alto Networks And CAGNY Conference AN2 Therapeutics reports FY results Seeking Alpha’s Quant Rating on AN2 Therapeutics Historical earnings data for AN2 Therapeutics ...
Message Board Posts | AN2 Therapeutics Inc. (NYSE:ANTX)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $ANTX News Article - AN2 Therapeutics to Present at Upcoming Investor Conferences | whytestocks | investorshangout | 11/02/2022 8:20:48 PM |
whytestocks: $ANTX News Article - NIH Awards Contract to AN2 Therapeutics Valued Up to $17.8 Million | whytestocks | investorshangout | 09/29/2022 2:05:48 PM |
whytestocks: $ANTX News Article - AN2 Therapeutics Reports Second Quarter 2022 Financial Results and | whytestocks | investorshangout | 08/11/2022 8:40:52 PM |
whytestocks: $ANTX News Article - AN2 Therapeutics Reports First Quarter 2022 Financial Results and | whytestocks | investorshangout | 05/10/2022 8:35:52 PM |
whytestocks: $ANTX News Article - AN2 Therapeutics Appoints Maggie FitzPatrick to Its Board of Direc | whytestocks | investorshangout | 05/09/2022 12:30:49 PM |
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) rose 4.6% to $128.28 on volume of 215,349,874 shares Zoomcar Holdings Inc. (ZCAR) rose 34.0% to $0.183 on volume of 204,010,215 shares Maxeon Solar Technologies Ltd. (MAXN) fell 3.5% to $0.1736 on volume of 2...
Plan to report Phase 2 topline results in August 2024 from ongoing Phase 2/3 trial (EBO-301) in treatment-refractory Mycobacterium avium Complex (TR-MAC) Phase 3 continues for 97 patients enrolled before the voluntary enrollment pause; lifting of the Phase 3 enrollment pause to be determi...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...